Amylyx Pharmaceuticals (AMLX) EBITDA Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) posted quarterly EBITDA Margin of 6392.14% for Q4 2024, up 639036.0% year-over-year from N/an in Q1 2024, and up 135.15% quarter-over-quarter from 18187.74% in Q3 2024.
Amylyx Pharmaceuticals (AMLX) EBITDA Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals' EBITDA Margin history runs 4 years deep, the most recent figure standing at 6392.14% for Q4 2024.
- In Q4 2024, EBITDA Margin rose 639036.0% year-over-year to 6392.14%; the TTM figure through Sep 2025 stood at 24739.15% (up 2487623.0% YoY), while the FY2024 annual figure was 360.1%, down 37029.0% from the prior year.
- EBITDA Margin for Q4 2024 stood at 6392.14%, up from 18187.74% in the prior quarter.
- The five-year high for EBITDA Margin was 6392.14% in Q4 2024, with the low at 18187.74% in Q3 2024.
- The 4-year median for EBITDA Margin is 137.78% (2024), against an average of 3949.77%.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin jumped 1586779 bps in 2023, then tumbled 1820597 bps in 2024.
- Amylyx Pharmaceuticals' EBITDA Margin stood at 8041.4% in 2021, then soared by 97 bps to 203.76% in 2022, then surged by 101 bps to 1.78% in 2023, then surged by 358339 bps to 6392.14% in 2024.
- Business Quant data shows AMLX's EBITDA Margin at 6392.14% in Q4 2024, 18187.74% in Q3 2024, and 7457.09% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.36 Bn | 4.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6,392.14% |
| Sep 30, 2024 | -18,187.74% |
| Jun 30, 2024 | -7,457.09% |
| Mar 31, 2024 | -137.78% |
| Dec 31, 2023 | 1.78% |
| Sep 30, 2023 | 18.23% |
| Jun 30, 2023 | 20.57% |
| Mar 31, 2023 | -2.87% |
| Dec 31, 2022 | -203.76% |
| Sep 30, 2022 | -15,849.57% |
| Sep 30, 2021 | -8,041.40% |